ArticleiScience2026
Systemic immune-inflammatory index for the prediction of the survival in patients with cervical cancer: A meta-analysis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic inflammation is increasingly recognized as a key determinant of cancer outcomes, and composite blood-based indices may provide clinically useful prognostic information. The systemic immune-inflammatory index (SII), integrating neutrophil, lymphocyte, and platelet counts, reflects the balance between tumor-promoting inflammation, and antitumor immunity. In this meta-analysis, we synthesized evidence from 14 longitudinal studies including 2,820 patients with cervical cancer to evaluate the association between pretreatment SII and survival outcomes. Using random-effects models, elevated SII was consistently associated with poorer overall survival and progression-free survival across diverse clinical settings, treatment modalities, and analytic approaches, with particularly strong associations observed in Asian populations. Conceptually, these findings highlight the prognostic relevance of systemic immune-inflammatory status in cervical cancer progression. Given its low cost, accessibility, and reproducibility, SII may represent a practical tool for risk stratification and treatment planning, while underscoring the need for prospective studies to define standardized thresholds and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.